nivolumab,ipilimumab
bms
['ipi/', 'check,mate,914', 'rcc,(-irccs),(-srcc),(-urcc)', 'nivo', 'checkmate 914']
checkmate 914(a): no additional benefit for adj ipi/nivo for primary endpoint dfs for loc #rcc but discontinuation due to aes #esmo22 
Research Fellow @myESMO @TheChristieNHS #CPOClab | Medical Oncologist @COBLH | PhD candidate @syd_health @GarvanInstitute | Traveller, Hiker | Opinions my own